Treatment of focal cerebral ischemia with liposomal nerve growth factor

Yun On Luk, Winby York Kwan Chen, Wen Jang Wong, Han Hwa Hu, Li Chi Hsu, Chang Ming Chern, Kuo Jung Huang, Sai Lung Law

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Liposomal nerve growth factor (NGF) was used for the treatment of focal cerebral ischemia in a rat model. Positive charge inducing agents of sphingosine (SP) and stearylamine (S) were formulated in the liposomal NGF. Dose-response of intraventricular injection of liposomal NGF showed significant reduction in infarct volume at the dose of 5 and 10 μg/rat of NGF. The liposomal NGF formulated with SP or S demonstrated similar results in the reduction of total infarct volume in rats. When we increased the molar ratio of SP and S from 0.15 to 0.3, the infarct volume from rats showed a similar value as that of the control treated with NGF solution. Liposomal NGF was given prior to the development of ischemia. We found that NGF was effective in prevention of neuronal death. The NGF concentrations in brain for liposomal NGF were maintained in a level significantly higher than those for NGF solution. This was attributed to the positively charged liposomal NGF bound effectively in brain ventricle and caused longer retention time than free NGF for localization in brain. Therefore, the effect of liposomal NGF on reduction of infarct volume was significant. We assumed that the transportation of NGF might go through the cerebrospinal fluid pathway throughout the ventricular system and subarachnoid system to cerebral cortex to produce a therapeutic effect on ischemia.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalDrug Delivery: Journal of Delivery and Targeting of Therapeutic Agents
Volume11
Issue number5
DOIs
Publication statusPublished - Sep 1 2004
Externally publishedYes

Fingerprint

Nerve Growth Factor
Brain Ischemia
Therapeutics
Sphingosine
Brain
Ischemia
Intraventricular Injections
Therapeutic Uses
Cerebral Cortex
Cerebrospinal Fluid

Keywords

  • Focal Cerebral Ischemia
  • Infarct Volume
  • Intraventricular Injection
  • Liposome
  • Nerve Growth Factor
  • Stroke

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Treatment of focal cerebral ischemia with liposomal nerve growth factor. / Luk, Yun On; Chen, Winby York Kwan; Wong, Wen Jang; Hu, Han Hwa; Hsu, Li Chi; Chern, Chang Ming; Huang, Kuo Jung; Law, Sai Lung.

In: Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents, Vol. 11, No. 5, 01.09.2004, p. 319-324.

Research output: Contribution to journalArticle

Luk, Yun On ; Chen, Winby York Kwan ; Wong, Wen Jang ; Hu, Han Hwa ; Hsu, Li Chi ; Chern, Chang Ming ; Huang, Kuo Jung ; Law, Sai Lung. / Treatment of focal cerebral ischemia with liposomal nerve growth factor. In: Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents. 2004 ; Vol. 11, No. 5. pp. 319-324.
@article{bc0a17076eb541f69b1d7e32e3650ae9,
title = "Treatment of focal cerebral ischemia with liposomal nerve growth factor",
abstract = "Liposomal nerve growth factor (NGF) was used for the treatment of focal cerebral ischemia in a rat model. Positive charge inducing agents of sphingosine (SP) and stearylamine (S) were formulated in the liposomal NGF. Dose-response of intraventricular injection of liposomal NGF showed significant reduction in infarct volume at the dose of 5 and 10 μg/rat of NGF. The liposomal NGF formulated with SP or S demonstrated similar results in the reduction of total infarct volume in rats. When we increased the molar ratio of SP and S from 0.15 to 0.3, the infarct volume from rats showed a similar value as that of the control treated with NGF solution. Liposomal NGF was given prior to the development of ischemia. We found that NGF was effective in prevention of neuronal death. The NGF concentrations in brain for liposomal NGF were maintained in a level significantly higher than those for NGF solution. This was attributed to the positively charged liposomal NGF bound effectively in brain ventricle and caused longer retention time than free NGF for localization in brain. Therefore, the effect of liposomal NGF on reduction of infarct volume was significant. We assumed that the transportation of NGF might go through the cerebrospinal fluid pathway throughout the ventricular system and subarachnoid system to cerebral cortex to produce a therapeutic effect on ischemia.",
keywords = "Focal Cerebral Ischemia, Infarct Volume, Intraventricular Injection, Liposome, Nerve Growth Factor, Stroke",
author = "Luk, {Yun On} and Chen, {Winby York Kwan} and Wong, {Wen Jang} and Hu, {Han Hwa} and Hsu, {Li Chi} and Chern, {Chang Ming} and Huang, {Kuo Jung} and Law, {Sai Lung}",
year = "2004",
month = "9",
day = "1",
doi = "10.1080/10717540490494104",
language = "English",
volume = "11",
pages = "319--324",
journal = "Drug Delivery",
issn = "1071-7544",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Treatment of focal cerebral ischemia with liposomal nerve growth factor

AU - Luk, Yun On

AU - Chen, Winby York Kwan

AU - Wong, Wen Jang

AU - Hu, Han Hwa

AU - Hsu, Li Chi

AU - Chern, Chang Ming

AU - Huang, Kuo Jung

AU - Law, Sai Lung

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Liposomal nerve growth factor (NGF) was used for the treatment of focal cerebral ischemia in a rat model. Positive charge inducing agents of sphingosine (SP) and stearylamine (S) were formulated in the liposomal NGF. Dose-response of intraventricular injection of liposomal NGF showed significant reduction in infarct volume at the dose of 5 and 10 μg/rat of NGF. The liposomal NGF formulated with SP or S demonstrated similar results in the reduction of total infarct volume in rats. When we increased the molar ratio of SP and S from 0.15 to 0.3, the infarct volume from rats showed a similar value as that of the control treated with NGF solution. Liposomal NGF was given prior to the development of ischemia. We found that NGF was effective in prevention of neuronal death. The NGF concentrations in brain for liposomal NGF were maintained in a level significantly higher than those for NGF solution. This was attributed to the positively charged liposomal NGF bound effectively in brain ventricle and caused longer retention time than free NGF for localization in brain. Therefore, the effect of liposomal NGF on reduction of infarct volume was significant. We assumed that the transportation of NGF might go through the cerebrospinal fluid pathway throughout the ventricular system and subarachnoid system to cerebral cortex to produce a therapeutic effect on ischemia.

AB - Liposomal nerve growth factor (NGF) was used for the treatment of focal cerebral ischemia in a rat model. Positive charge inducing agents of sphingosine (SP) and stearylamine (S) were formulated in the liposomal NGF. Dose-response of intraventricular injection of liposomal NGF showed significant reduction in infarct volume at the dose of 5 and 10 μg/rat of NGF. The liposomal NGF formulated with SP or S demonstrated similar results in the reduction of total infarct volume in rats. When we increased the molar ratio of SP and S from 0.15 to 0.3, the infarct volume from rats showed a similar value as that of the control treated with NGF solution. Liposomal NGF was given prior to the development of ischemia. We found that NGF was effective in prevention of neuronal death. The NGF concentrations in brain for liposomal NGF were maintained in a level significantly higher than those for NGF solution. This was attributed to the positively charged liposomal NGF bound effectively in brain ventricle and caused longer retention time than free NGF for localization in brain. Therefore, the effect of liposomal NGF on reduction of infarct volume was significant. We assumed that the transportation of NGF might go through the cerebrospinal fluid pathway throughout the ventricular system and subarachnoid system to cerebral cortex to produce a therapeutic effect on ischemia.

KW - Focal Cerebral Ischemia

KW - Infarct Volume

KW - Intraventricular Injection

KW - Liposome

KW - Nerve Growth Factor

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=4944256620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4944256620&partnerID=8YFLogxK

U2 - 10.1080/10717540490494104

DO - 10.1080/10717540490494104

M3 - Article

C2 - 15742557

AN - SCOPUS:4944256620

VL - 11

SP - 319

EP - 324

JO - Drug Delivery

JF - Drug Delivery

SN - 1071-7544

IS - 5

ER -